Analysts at Berenberg Bank provided their views on BioNTech SE (NASDAQ:BNTX), stating that the shares are substantially undervalued. The analysts believe the company’s current valuation only captures the COVID-19 vaccine potential, leaving the broad pipeline and technology platform unrecognized.

Near term, the analysts think likely positive news from the variant-adapted COVID-19 vaccine and flu vaccine will support the stock to move towards their price target, which was lowered to $350 from $400 due to model adjustments.

A confluence of evidence suggests SARS-CoV-2 is here to stay, and the analysts believe the COVID-19 vaccine will remain a multi-billion-dollar franchise in the foreseeable future. Their thesis on the longevity of the COVID-19 vaccine business remains unchanged.

What gives them the most confidence is the experts’ opinion at FDA advisory committee meeting last week, according to which the COVID-19 vaccine will need an update ahead of the coming winter season. 80% of protection against hospitalization/death is a bar for success, which the analysts think is easy to overcome. Therefore, they believe the data on the omicron-based vaccine in April is likely to be positive. Their checks with U.S. payers suggest a potential upside in both the volume and the price.